Published in Drug Week, October 1st, 2004
Boston Scientific said it has enrolled nearly 3700 patients worldwide in the registry, which has been designed to assess physician usage patterns and evaluate outcome data for the Taxus Express(2) paclitaxel-eluting coronary stent system in "real world" patients.
The Milestone II registry has enrolled 1907 patients in Europe alone, where 118 centers were closely monitored. Analysis of the data was presented by Boston Scientific at the European Society of Cardiology's (ESC)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.